Affiliation:
1. From the David Geffen School of Medicine at University of California at Los Angeles; VA Greater Los Angeles Healthcare System, Los Angeles; RAND Health, Santa Monica; University of California, Irvine, Irvine, CA; and Johns Hopkins University, Baltimore, MD
Abstract
The experience of patients living with cancer and being treated with chemotherapy often includes the symptoms of nausea and vomiting. To provide a framework for high-quality management of these symptoms, we developed a set of key targeted evidence-based standards through an iterative process of targeted systematic review, development, and refinement of topic areas and standards and consensus ratings by a multidisciplinary expert panel as part of the RAND Cancer Quality–Assessing Symptoms Side Effects and Indicators of Supportive Treatment Project. For nausea and vomiting, key clinical standards included screening at the initial outpatient and inpatient visit, prophylaxis for acute and delayed emesis in patients receiving moderate to highly emetic chemotherapy, and follow-up after treatment for nausea and vomiting symptoms. In addition, patients with cancer and small bowel obstruction were examined as a special subset of patients who present with nausea and vomiting. The standards presented here for preventing and managing nausea and vomiting in cancer care should be incorporated into care pathways and should become the expectation rather than the exception.
Publisher
American Society of Clinical Oncology (ASCO)
Reference53 articles.
1. Morran C, Smith DC, Anderson DA, et al: Incidence of nausea and vomiting with cytotoxic chemotherapy: A prospective randomised trial of antiemetics. Br Med J 1:1323,1979-1324,
2. Predicting development of anticipatory nausea in cancer patients: Prospective examination of eight clinical characteristics
3. Wilcox PM, Fetting JH, Nettesheim KM, et al: Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treat Rep 66:1601,1982-1604,
4. National Comprehensive Cancer Network: Antiemesis. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf
5. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
Cited by
100 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献